{"id":35483,"date":"2020-12-21T12:36:35","date_gmt":"2020-12-21T12:36:35","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=35483"},"modified":"2023-05-10T15:17:41","modified_gmt":"2023-05-10T14:17:41","slug":"oren-beske","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/","title":{"rendered":"Oren Beske"},"content":{"rendered":"
\n\n\t

Oren Beske, Ph.D.<\/h2>\n

Amalgamator of Business and Biology at ATUM<\/h4>\n\t

Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry.<\/p>\n

Most recently, he served as the CEO of Alloy Therapeutics, Inc. a start up antibody discovery platform company. Dr. Beske received a BS in Physiology and Biochemistry from CSULB and his Ph.D. in Cell Biology from UC San Francisco.<\/p>\n\t\t\t\t\t\t\t\"Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Gallery\"\t\t\t\t\t\t\t\n

\n\tTitle: Leap In Transposase Platform: From shiny and new to tried and true\n\t<\/h3>\n\t

Since the LeapIn Transposase platform was launched for biotherapeutic cell\u00a0line development approximately\u00a0three years ago, the market adoption has been robust and it has rapidly become well accepted in the industry.\u00a0 This talk will highlight a few key milestones from these past few years but will focus on how the platform will be evolving\u00a0for future applications\u00a0… including case studies around our COVID response, chain ratio balancing for complex molecules and how the technology platform can be used to reduce target gene expression.<\/p>\n\t\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n

\n\t\t\t\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t

https:\/\/www.atum.bio\/<\/a><\/p>\n

\n\t\t\t\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t

Visit Profile<\/a><\/p>\n\n<\/div>","protected":false},"excerpt":{"rendered":"

Oren Beske, Ph.D. Amalgamator of Business and Biology at ATUM Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he…<\/p>\n","protected":false},"author":1,"featured_media":35484,"parent":34722,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-35483","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nOren Beske • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oren Beske • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-10T14:17:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/\",\"name\":\"Oren Beske • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg\",\"datePublished\":\"2020-12-21T12:36:35+00:00\",\"dateModified\":\"2023-05-10T14:17:41+00:00\",\"description\":\"Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Engineering & Therapeutics 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Oren Beske\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oren Beske • BioTech Pharma Summit","description":"Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/","og_locale":"en_US","og_type":"article","og_title":"Oren Beske • BioTech Pharma Summit","og_description":"Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-05-10T14:17:41+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/","name":"Oren Beske • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg","datePublished":"2020-12-21T12:36:35+00:00","dateModified":"2023-05-10T14:17:41+00:00","description":"Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Oren_Beske_Photo_ATUM_BioTech_Pharma_Summit_Profile.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/oren-beske\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Antibody Engineering & Therapeutics 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Oren Beske"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=35483"}],"version-history":[{"count":7,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35483\/revisions"}],"predecessor-version":[{"id":38355,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35483\/revisions\/38355"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/35484"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=35483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}